Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...

When patients begin receiving care at St. Luke's Same Day Surgery Center in April, they'll receive medications through a computerized pharmacy system that's been in use throughout St. Luke's Regional ...